A longitudinal analysis of the completeness of maternal HIV testing, including repeat testing in Cape Town, South Africa.
Adolescent
Adult
Female
HIV Infections
/ blood
Humans
Infectious Disease Transmission, Vertical
/ prevention & control
Longitudinal Studies
Mass Screening
Middle Aged
Pregnancy
Pregnancy Complications, Infectious
/ blood
Prenatal Care
Retrospective Studies
Serologic Tests
South Africa
/ epidemiology
Young Adult
HIV
PMTCT
South Africa
guideline implementation
maternal HIV testing
repeat testing
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
05
04
2019
accepted:
04
12
2019
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
21
10
2020
Statut:
ppublish
Résumé
The virtual elimination of mother-to-child transmission of HIV cannot be achieved without complete maternal HIV testing. The World Health Organization recommends that women in high HIV prevalent settings repeat HIV testing in the third trimester, and at delivery or directly thereafter. The Western Cape Province (South Africa) prevention of mother-to-child transmission (PMTCT) guidelines recommend a repeat maternal HIV test between 32 and 34 weeks gestation and at delivery in addition to testing at the first antenatal visit (ideally <20 weeks gestation). There are few published longitudinal studies on the uptake of initial and repeated maternal HIV testing programmes in sub-Saharan Africa. We aimed to investigate the implementation of initial and repeat maternal HIV testing guidelines in Cape Town, South Africa. Between 2013 and 2016 we established an electronic PMTCT register that consolidated routine data from a primary healthcare facility and its secondary and tertiary referral sites in Cape Town. This provided a longitudinal record for each participant, from first antenatal visit to delivery. Utilizing these data, we conducted a retrospective analysis investigating the completeness of maternal HIV testing according to the PMTCT HIV testing guidelines in Cape Town, and predictors of complete testing, from 2014 to 2016. Among 8558 enrolled pregnant women, 7213 (84%) were not known to be HIV positive at their first visit and thus eligible for HIV testing; 91% of them received ≥1 HIV test during pregnancy/delivery. Testing at the first visit was 98% among the 85% of women who attended antenatal care. Among women eligible to receive all three recommended HIV tests, only 11% achieved all three tests. Delivery HIV testing completion among all women without an HIV-positive diagnosis was 23%. HIV prevalence at delivery was 21% and HIV incidence between first visit and delivery in those with ≥2 HIV tests was 0.2%. Women who enrolled after 2014 were more likely to receive the three recommended tests (aOR: 1.41; 95% CI: 1.10 to 1.81) and retest at delivery (aOR: 1.20; 95% CI: 1.05 to 1.39). Implementation of maternal HIV testing in Cape Town improved between 2014 and 2016 but major gaps remain, particularly at delivery.
Identifiants
pubmed: 31997583
doi: 10.1002/jia2.25441
pmc: PMC6989397
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25441Subventions
Organisme : NICHD NIH HHS
ID : R01 HD075156
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
J Int AIDS Soc. 2018 Nov;21(11):e25212
pubmed: 30480373
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):e85-91
pubmed: 21436709
J Int AIDS Soc. 2016 Jan 18;19(1):20605
pubmed: 26787516
Trop Med Int Health. 2016 Feb;21(2):202-9
pubmed: 26555353
PLoS One. 2015 May 05;10(5):e0125525
pubmed: 25942423
MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):148-51
pubmed: 23446514
Lancet. 2005 Oct 1;366(9492):1182-8
pubmed: 16198767
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):417-25
pubmed: 22193774
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):199-204
pubmed: 22343175
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):e77-83
pubmed: 25585302
PLoS One. 2018 Dec 28;13(12):e0209782
pubmed: 30592749
PLoS One. 2018 Aug 9;13(8):e0201886
pubmed: 30092104
BMC Pediatr. 2008 Sep 04;8:34
pubmed: 18771599
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958218823530
pubmed: 30798664
J Int AIDS Soc. 2019 Apr;22(4):e25271
pubmed: 30958644
J Int AIDS Soc. 2017 Dec;20(4):
pubmed: 29236362
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):e45-8
pubmed: 21084998
J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):408-15
pubmed: 12447012